An increasing incidence of invasive fungal infections is observed in most immunocompromised patients, and especially leukaemia patients. In order to decrease the mortality due to these infections, the clinicians need to optimise their treatment choices for the most common fungal infections observed in this population: invasive aspergillosis and candidiasis. These recommendations have been developed by an expert panel following an evidence-based search of the literature assessing the role of antifungal therapies in the treatment of patients with acute leukaemia or bone marrow transplantation and invasive candidiasis – including candidaemia – and aspergillosis. We present results from a questionnaire on the current practice among experts in Europe, show results of the literature search and provide the panel’s recommendations.